KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Choosing the best first-line therapy for extensive-stage small-cell lung cancer: anti-PD-1 or anti-PD-L1 inhibitors?

Shengyu Zhu, Jianjiang Liu, Xialin Chen, Sheng Jin

Medicine (Baltimore) 104(36) e44383

PMID40922293
PMCIDPMC12419250
DOI10.1097/MD.0000000000044383
发表日期2025-09-09
摘要

摘要

BACKGROUND: This study addresses the lack of a comprehensive meta-analysis comparing the efficacy and safety of first-line anti-blocking the programmed cell death 1 (PD-1) and anti-programmed death ligand 1 (PD-L1) therapies in patients with extensive-stage small-cell lung cancer, using reconstructed individual patient data. METHODS: Through systematic review, we extracted relevant studies from PubMed and EMBASE databases, spanning January 1, 2010 to November 28, 2024. Only phase III randomized controlled trials assessing anti-PD-1 inhibitors plus chemotherapy (CT) versus anti-PD-L1 inhibitors plus CT were selected. To compare survival outcomes, we employed WebPlotDigitizer and R software for survival curve reconstruction, aiming to elucidate the comparative effectiveness and safety of the 2 therapies. RESULTS: Our analysis of 7 randomized controlled trials, involving 3339 patients, revealed no significant difference in progression-free survival (PFS) or overall survival (OS) between anti-PD-1 inhibitors plus CT and anti-PD-L1 inhibitors plus CT. The combined 6-, 12-, and 18-month PFS rates were 42.4% versus 43.3%, 19.9% versus 17.0%, and 14.6% versus 13.6% for the anti-PD-1 and anti-PD-L1 groups, respectively (hazard ratio: 0.98, 95% confidence interval: 0.88-1.09, P = .691). The combined 6-, 12-, 18-, and 24-month OS rates were 86.6% versus 85.5%, 58.7% versus 56.9%, 38.8% versus 36.8%, and 28.9% versus 25.4% for the anti-PD-1 and anti-PD-L1 groups, respectively (hazard ratio: 0.94, 95% confidence interval: 0.84-1.06, P = .305). The analysis showed a slightly lower incidence of grade ≥3 adverse events (AEs), serious AEs, any-grade immune-related adverse events, grade ≥3 immune-related adverse events, and events leading to death or treatment discontinuation in the anti-PD-L1 group compared to the anti-PD-1 group (P < .001). However, no significant differences were observed in the risk of any-grade AEs. CONCLUSION: This research provides detailed analyses of PFS, OS, and treatment safety for these 2 treatment regimens, making it a valuable resource for clinicians in routine care. Our results demonstrate that both anti-PD-1 and anti-PD-L1 therapies, when combined with chemotherapy, are equally effective. However, anti-PD-L1 therapies appear to offer a safer first-line treatment option for extensive-stage small-cell lung cancer.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。